A phase I, open-label, dose-seeking study of AZD2171 [cediranib] given daily orally in combination with standard chemotherapy regimens (CT) in patients with advanced incurable non-small cell lung cancer (NSCLC) or colorectal cancer or other tumor types suitable for treatment with capecitabine.

Trial Profile

A phase I, open-label, dose-seeking study of AZD2171 [cediranib] given daily orally in combination with standard chemotherapy regimens (CT) in patients with advanced incurable non-small cell lung cancer (NSCLC) or colorectal cancer or other tumor types suitable for treatment with capecitabine.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Nov 2016

At a glance

  • Drugs Cediranib (Primary) ; Capecitabine; Carboplatin; Paclitaxel
  • Indications Colorectal cancer; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Jan 2011 Actual End Date (1 Jan 2011) added as reported by ClinicalTrials.gov.
    • 18 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 26 May 2010 Planned end date changed from 1 Jun 2009 to 1 Nov 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top